SG11202106214YA - Novel anti-ccr8 antibody - Google Patents
Novel anti-ccr8 antibodyInfo
- Publication number
- SG11202106214YA SG11202106214YA SG11202106214YA SG11202106214YA SG11202106214YA SG 11202106214Y A SG11202106214Y A SG 11202106214YA SG 11202106214Y A SG11202106214Y A SG 11202106214YA SG 11202106214Y A SG11202106214Y A SG 11202106214YA SG 11202106214Y A SG11202106214Y A SG 11202106214YA
- Authority
- SG
- Singapore
- Prior art keywords
- novel anti
- ccr8 antibody
- ccr8
- antibody
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018245044 | 2018-12-27 | ||
| JP2019099923 | 2019-05-29 | ||
| PCT/JP2019/051603 WO2020138489A1 (ja) | 2018-12-27 | 2019-12-27 | 新規抗ｃｃｒ８抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202106214YA true SG11202106214YA (en) | 2021-07-29 |
Family
ID=71128288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202106214YA SG11202106214YA (en) | 2018-12-27 | 2019-12-27 | Novel anti-ccr8 antibody |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220064312A1 (de) |
| EP (1) | EP3903817A4 (de) |
| JP (3) | JP6894086B2 (de) |
| KR (1) | KR20210108996A (de) |
| CN (1) | CN113260381A (de) |
| AU (1) | AU2019415395A1 (de) |
| BR (1) | BR112021011431A2 (de) |
| CA (1) | CA3124332A1 (de) |
| MX (1) | MX2021007576A (de) |
| SA (1) | SA521422394B1 (de) |
| SG (1) | SG11202106214YA (de) |
| TW (1) | TW202039575A (de) |
| WO (1) | WO2020138489A1 (de) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3616720T3 (da) | 2017-03-29 | 2021-03-29 | Shionogi & Co | Farmaceutisk sammensætning til cancerbehandling |
| JP6894086B2 (ja) * | 2018-12-27 | 2021-06-23 | 塩野義製薬株式会社 | 新規抗ｃｃｒ８抗体 |
| US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
| IL296673A (en) | 2020-03-23 | 2022-11-01 | Bristol Myers Squibb Co | Anti-ccr8 antibodies for cancer treatment |
| TW202216771A (zh) | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
| WO2022004760A1 (ja) | 2020-06-30 | 2022-01-06 | 塩野義製薬株式会社 | 抗ｃｃｒ８抗体と化学療法剤の併用 |
| US20240228635A9 (en) * | 2020-08-28 | 2024-07-11 | B7 Therapeutics Inc. | Ccr8 antibody and application thereof |
| US20230416382A1 (en) * | 2020-10-14 | 2023-12-28 | Five Prime Therapeutics, Inc. | Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof |
| CA3198647A1 (en) * | 2020-10-16 | 2022-04-21 | LaNova Medicines Limited | Anti-ccr8 monoclonal antibodies and uses thereof |
| WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
| JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト |
| EP4267617A1 (de) | 2020-12-24 | 2023-11-01 | Vib Vzw | Menschliche ccr8-bindemittel |
| EP4267618A1 (de) | 2020-12-24 | 2023-11-01 | Vib Vzw | Nichtblockierende, menschliche ccr8-bindemittel |
| CA3206125A1 (en) | 2020-12-24 | 2022-06-30 | Vib Vzw | Murine cross-reactive human ccr8 binders |
| CN114805569A (zh) * | 2021-01-29 | 2022-07-29 | 北京伟峰益民科技有限公司 | 一种抗人ccl1抗体及其应用 |
| EP4317439A1 (de) | 2021-03-31 | 2024-02-07 | Shionogi & Co., Ltd | Chimärer antigenrezeptor, der ccr8 als antigen erkennt |
| UY39798A (es) * | 2021-06-04 | 2022-12-30 | Amgen Inc | Anticuerpos anti-ccr8 y usos de los mismos |
| KR20240019218A (ko) * | 2021-06-04 | 2024-02-14 | 암젠 리서치 (뮌헨) 게엠베하 | T 세포 관여자 분자 및 이의 용도 |
| KR20240032889A (ko) | 2021-07-14 | 2024-03-12 | 제넨테크, 인크. | 항-c-c 모티프 케모카인 수용체 8(ccr8) 항체 및 사용 방법 |
| AU2022317803A1 (en) | 2021-07-27 | 2023-10-26 | Abbvie Inc. | Anti-ccr8 antibodies |
| JP2024531409A (ja) * | 2021-08-20 | 2024-08-29 | ハイファイバイオ， インコーポレイテッド | 抗ｃｃｒ８抗体およびその使用 |
| WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
| IL313177A (en) * | 2021-12-02 | 2024-07-01 | Zai Lab Shanghai Co Ltd | CCR8 antigen binding unit and its uses |
| CA3239528A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| AU2022417491A1 (en) | 2021-12-22 | 2024-05-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN118742637A (zh) * | 2021-12-23 | 2024-10-01 | 乐普创一生物科技（上海）有限公司 | 抗ccr8抗体及其应用 |
| US20230279130A1 (en) * | 2022-01-14 | 2023-09-07 | Qilu Puget Sound Biotherapeutics Corporation | Anti-ccr8 antibodies |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| EP4245756B1 (de) | 2022-03-17 | 2024-10-09 | Gilead Sciences, Inc. | Degrader der ikaros-zinkfingerfamilie und verwendungen davon |
| CN116789820A (zh) * | 2022-03-18 | 2023-09-22 | 北京天诺健成医药科技有限公司 | 一种新型免疫调节剂的开发和应用 |
| US20230374036A1 (en) | 2022-04-21 | 2023-11-23 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2023206350A1 (en) * | 2022-04-29 | 2023-11-02 | Analytical Biosciences Shanghai Limited | Anti-ccr8 antibodies and uses thereof |
| WO2023219147A1 (ja) * | 2022-05-13 | 2023-11-16 | 塩野義製薬株式会社 | Ｃｃｒ８検出用新規抗ｃｃｒ８抗体 |
| WO2023230473A1 (en) | 2022-05-24 | 2023-11-30 | Bristol-Myers Squibb Company | Antibodies that bind to human ccr8 |
| WO2023240135A2 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | Bifunctional chelators and conjugates |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024008110A1 (zh) * | 2022-07-07 | 2024-01-11 | 四川思柏沃生物技术有限公司 | 抗ccr8抗体及其应用 |
| WO2024027823A1 (en) * | 2022-08-04 | 2024-02-08 | Beigene, Ltd. | Anti-ccr8 antibodies and methods of use |
| TW202426498A (zh) | 2022-09-09 | 2024-07-01 | 德商拜耳廠股份有限公司 | Ccr8抗體之醫藥用途及給藥計劃 |
| WO2024062076A1 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2024062082A1 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2024062072A2 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2024077239A1 (en) | 2022-10-07 | 2024-04-11 | Genentech, Inc. | Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies |
| TW202423987A (zh) * | 2022-12-07 | 2024-06-16 | 大陸商廣東菲鵬製藥股份有限公司 | 抗ccr8抗體及其應用 |
| WO2024137852A1 (en) | 2022-12-22 | 2024-06-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024165468A1 (en) | 2023-02-06 | 2024-08-15 | Bayer Aktiengesellschaft | Combination of ccr8 antibodies with dgk inhibitors in the treatment of cancer |
| WO2024204440A1 (ja) * | 2023-03-28 | 2024-10-03 | 株式会社エヌビィー健康研究所 | 抗体、核酸、細胞、及び医薬 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7949394A (en) | 1993-11-19 | 1995-06-06 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human medulloblastomatous cell |
| DE69535243T2 (de) | 1994-07-13 | 2007-05-10 | Chugai Seiyaku K.K. | Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper |
| WO1998013388A1 (fr) | 1996-09-26 | 1998-04-02 | Chugai Seiyaku Kabushiki Kaisha | Anticorps contre les peptides lies a la parathormone humaine |
| WO1999006561A2 (en) * | 1997-07-29 | 1999-02-11 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health | Chemokine receptor ccr8 dna and uses thereof |
| ZA9810371B (en) * | 1997-11-13 | 1999-08-30 | Schering Corp | Th2 cell depletion; compositions; methods. |
| US6762341B2 (en) * | 2000-02-10 | 2004-07-13 | Schering Corporation | Uses of mammalian CCR8 receptors and related reagents |
| BR0114475A (pt) | 2000-10-06 | 2003-12-23 | Kyowa Hakko Kogyo Kk | Célula para a produção de composição de anticorpo |
| AU2004279742A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Fused protein composition |
| WO2007044756A2 (en) * | 2005-10-11 | 2007-04-19 | Icos Corporation | Monoclonal antibodies recognizing human ccr8 |
| WO2013131010A2 (en) * | 2012-03-02 | 2013-09-06 | Icahn School Of Medicine At Mount Sinai | Function of chemokine receptor ccr8 in melanoma metastasis |
| US10087259B1 (en) | 2014-04-28 | 2018-10-02 | Memorial Sloan Kettering Cancer Center | Depleting tumor-specific tregs |
| JP7358047B2 (ja) * | 2016-05-16 | 2023-10-10 | チェックマブ エス．アール．エル． | 腫瘍浸潤制御性ｔ細胞において選択的に脱制御されたマーカー |
| WO2018112032A1 (en) | 2016-12-13 | 2018-06-21 | President And Fellows Of Harvard College | Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8 |
| DK3616720T3 (da) * | 2017-03-29 | 2021-03-29 | Shionogi & Co | Farmaceutisk sammensætning til cancerbehandling |
| WO2019157098A1 (en) * | 2018-02-06 | 2019-08-15 | Advaxis, Inc. | Compositions comprising a recombinant listeria strain and an anti-ccr8 antibody and methods of use |
| JP6894086B2 (ja) * | 2018-12-27 | 2021-06-23 | 塩野義製薬株式会社 | 新規抗ｃｃｒ８抗体 |
-
2019
- 2019-12-27 JP JP2020538152A patent/JP6894086B2/ja active Active
- 2019-12-27 KR KR1020217023411A patent/KR20210108996A/ko unknown
- 2019-12-27 US US17/418,417 patent/US20220064312A1/en active Pending
- 2019-12-27 SG SG11202106214YA patent/SG11202106214YA/en unknown
- 2019-12-27 MX MX2021007576A patent/MX2021007576A/es unknown
- 2019-12-27 WO PCT/JP2019/051603 patent/WO2020138489A1/ja active Application Filing
- 2019-12-27 CA CA3124332A patent/CA3124332A1/en active Pending
- 2019-12-27 CN CN201980086253.6A patent/CN113260381A/zh active Pending
- 2019-12-27 TW TW108148111A patent/TW202039575A/zh unknown
- 2019-12-27 AU AU2019415395A patent/AU2019415395A1/en active Pending
- 2019-12-27 BR BR112021011431A patent/BR112021011431A2/pt unknown
- 2019-12-27 EP EP19905033.7A patent/EP3903817A4/de active Pending
-
2021
- 2021-03-05 JP JP2021034895A patent/JP7452818B2/ja active Active
- 2021-06-24 SA SA521422394A patent/SA521422394B1/ar unknown
-
2024
- 2024-02-28 JP JP2024028052A patent/JP2024059872A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3903817A4 (de) | 2022-08-17 |
| JP2024059872A (ja) | 2024-05-01 |
| CN113260381A (zh) | 2021-08-13 |
| EP3903817A1 (de) | 2021-11-03 |
| WO2020138489A1 (ja) | 2020-07-02 |
| BR112021011431A2 (pt) | 2021-11-23 |
| JP7452818B2 (ja) | 2024-03-19 |
| AU2019415395A1 (en) | 2021-07-15 |
| SA521422394B1 (ar) | 2024-05-09 |
| JP2021101710A (ja) | 2021-07-15 |
| TW202039575A (zh) | 2020-11-01 |
| MX2021007576A (es) | 2021-08-24 |
| CA3124332A1 (en) | 2020-07-02 |
| JPWO2020138489A1 (ja) | 2021-02-18 |
| US20220064312A1 (en) | 2022-03-03 |
| JP6894086B2 (ja) | 2021-06-23 |
| KR20210108996A (ko) | 2021-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202106214YA (en) | Novel anti-ccr8 antibody | |
| IL279321A (en) | Anti-SIRPalpha antibody | |
| IL280780A (en) | Anti-TIGIT antibodies | |
| IL280013A (en) | Anti-IL36R antibodies | |
| IL279352A (en) | IL-11RA antibodies | |
| IL278010A (en) | Antibodies to galectin 10 | |
| IL273393A (en) | New epsilon anti-CD3 antibodies | |
| IL277030A (en) | Antibodies | |
| GB202110263D0 (en) | Anti-btla antibodies | |
| ZA202101177B (en) | Anti-btla antibody | |
| GB201811368D0 (en) | Antibody | |
| GB201817172D0 (en) | Antibody | |
| IL281594A (en) | Antibodies against KLRG1 | |
| GB201905150D0 (en) | Ant-ige antibodies | |
| ZA202108836B (en) | Anti-epha4 antibody | |
| EP4083211A4 (de) | Anti-cdcp1-antikörper | |
| GB201806084D0 (en) | Antibodies | |
| GB201917480D0 (en) | Antibodies | |
| GB201900732D0 (en) | Antibodies | |
| SG11202105718TA (en) | Modified antibodies | |
| GB201813597D0 (en) | Antibody | |
| GB201919062D0 (en) | Antibody | |
| GB201809945D0 (en) | Antibody | |
| GB201819952D0 (en) | Antibodies | |
| GB201912008D0 (en) | Antibody |